Product Description: Sirukumab (CNTO-136) is a human monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab has the potential for active lupus nephritis research[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Brad H Rovin, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol. 2016 Sep;68(9):2174-83.
CAS Number: 1194585-53-9
Molecular Weight: 144.6 (kDa)
Compound Purity: 95.00
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related